After opening, the solution remains stable for up to 12 months when stored at room temperature and kept tightly sealed. Discard it sooner if the appearance changes or if it passes the printed expiry date.
Orahelp provides local anaesthesia for minor oral discomfort but is not intended as a substitute for dental anaesthetic techniques required during invasive procedures. A dentist should select an appropriate anesthetic for such work.
Topical salicylates can be absorbed systemically and may modestly enhance the anticoagulant effect of warfarin. Patients on chronic anticoagulation should discuss the use of Orahelp with their prescriber.
Lignocaine and salicylates are not prohibited substances under the World Anti-Doping Agency (WADA) code. Routine drug screens for sports typically do not detect therapeutic concentrations of these agents.
Small accidental ingestion is usually benign, but you may experience mild nausea or a transient metallic taste. Contact your local poison control centre or NHS 111 for advice, especially if larger amounts are consumed.
Orahelp is not licensed for children under 12 years of age. For pediatric oral irritation, a clinician should recommend an age-appropriate alternative.
The tingling is a result of lignocaine’s interaction with sensory nerves as it begins to block sodium channels. This sensation is a normal precursor to the numbing effect.
Dependence is not associated with topical NSAID-local anaesthetic combinations. However, persistent sore throat should be evaluated by a healthcare professional to rule out underlying pathology.
Many over-the-counter mouth rinses contain only a single active ingredient (e.g., chlorhexidine) at lower concentrations. Orahelp’s dual formulation offers both anti-inflammatory and anaesthetic actions at higher concentrations, providing faster and more comprehensive symptom relief under prescription guidance.
Yes. Orahelp in its original bottle complies with the UK Civil Aviation Authority liquid restrictions when the container is ≤100 ml and placed in a transparent, resealable plastic bag. Larger bottles must be checked in accordance with airline policies.
Orahelp is a topical preparation that contains choline salicylate and lignocaine as its active components. It is supplied as a clear solution in a 8.5 % / 2 % (w/v) concentration, packaged in a bottle for easy dispensing. The preparation belongs to the pain-relief and skin-care therapeutic categories and is regulated in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) as a prescription-only medicine (POM).
Choline Salicylate is a salicylate-based non-steroidal anti-inflammatory drug (NSAID). After topical application it penetrates the mucosal or skin layers and inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing the synthesis of prostaglandins that mediate pain, swelling, and redness.
Lignocaine (also known as lidocaine) is a local anaesthetic that blocks voltage-gated sodium channels on peripheral nerves. By stabilising the neuronal membrane, lignocaine prevents the initiation and propagation of pain impulses.
When combined, the two agents provide both an anti-inflammatory effect (from choline salicylate) and rapid local anaesthesia (from lignocaine), offering quicker symptomatic relief than either component alone. The onset of analgesia is typically within minutes, with the anti-inflammatory action becoming noticeable after several applications.
Orahelp is approved in the UK for the symptomatic relief of mild to moderate sore throat, oral ulceration, and minor mouth or lip discomfort caused by inflammation or trauma. It may also be used on small superficial skin irritations where a topical analgesic is appropriate, such as minor burns or insect bites, provided a healthcare professional determines it suitable.
Typical patients include adults and adolescents who require short-term relief of localized pain in the oral cavity or skin. The formulation is not intended for chronic use without medical supervision.
Ideal candidates are individuals without a history of hypersensitivity to salicylates or amide-type local anaesthetics, and who are not pregnant beyond the first trimester unless advised otherwise.
Special populations should be evaluated by a healthcare professional before initiating therapy.
If any of these serious reactions occur, seek immediate medical attention.
Patients should provide a full medication list-including over-the-counter drugs, herbal supplements, and other topical agents-to their prescriber.
Administration tips
Overdose and emergency measures
Discontinuation
Routine laboratory monitoring is not required for short-term use. Patients with chronic conditions, significant renal or hepatic disease, or those on multiple NSAIDs should have periodic assessment of kidney and liver function as part of their overall care plan.
This article provides educational information about Orahelp and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
